Author:
Hara Takahito,Kimura Akiko,Miyazaki Tohru,Tanaka Hiroshi,Morimoto Megumi,Nakai Katsuhiko,Soeda Junpei
Funder
Takeda Pharmaceutical Company
Reference28 articles.
1. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol. Cancer Ther.,2011
2. Cabozantinib, a MET/AXL/VEGFR triple inhibitor;Soeda;J. New Rem. Clin.,2019
3. Met, metastasis, motility and more;Birchmeier;Nat. Rev. Mol. Cell Biol.,2003
4. MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure;Boccaccio;Curr. Opin. Cell Biol.,2014
5. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities;Zhang;Mol. Cancer,2018
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献